A1237
Pramipexole dihydrochloride
>98% (HPLC), Dopamine D2 and D3 receptor agonist, powder
Sinonimo/i:
(S)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole dihydrochloride, PPX dihydrochloride
Autenticati per visualizzare i prezzi organizzativi e contrattuali.
Scegli un formato
Informazioni su questo articolo
Formula empirica (notazione di Hill):
C10H17N3S · 2HCl
Numero CAS:
Peso molecolare:
284.25
UNSPSC Code:
51111800
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Servizio Tecnico
Hai bisogno di aiuto? Il nostro team di scienziati qualificati è a tua disposizione.
Permettici di aiutartiServizio Tecnico
Hai bisogno di aiuto? Il nostro team di scienziati qualificati è a tua disposizione.
Permettici di aiutartiNome del prodotto
Pramipexole dihydrochloride, >98% (HPLC), powder
Quality Level
assay
>98% (HPLC)
form
powder
storage condition
desiccated
color
white to off-white
solubility
H2O: >20 mg/mL
originator
Boehringer Ingelheim
storage temp.
2-8°C
SMILES string
Cl.Cl.CCCN[C@H]1CCc2nc(N)sc2C1
InChI
1S/C10H17N3S.2ClH/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8;;/h7,12H,2-6H2,1H3,(H2,11,13);2*1H/t7-;;/m0../s1
InChI key
QMNWXHSYPXQFSK-KLXURFKVSA-N
Gene Information
human ... DRD2(1813), DRD3(1814), DRD4(1815)
Categorie correlate
General description
Pramipexole belongs to non-ergoline class and is derived from benzothiazole. It has strong affinity for D2 and D3 receptors (dopamine receptors) compared to other ergoline-derived drugs. However, it does not associate with non-dopamine receptors, for instance adrenergic and serotonin receptors.
Application
Pramipexole dihydrochloride has been used as D2 receptor agonist in dopamine (DA)-depleted striatum slices.
Pramipexole dihydrochloride has been used as a D2-like DR (dopaminergic receptor) agonist in study associated with Parkinson′s disease. It has also been used as a D2/D3 receptor agonist to study risky decision-making in rats.
Biochem/physiol Actions
Pramipexole dihydrochloride monohydrate is a dopamine agonist active at D3 and D2 receptor subtypes.
Pramipexole elicits neuroprotective role and may help in treating depression. It also has a potential to modulate limb movement and may be effective in treating restless legs syndrome.
Pramipexole is a dopamine agonist active at D3 and D2 receptor subtypes. Pramipexole has been found to have neuroprotective effects independent of its dopamine receptor agonism. It reduces mitochondrial reactive oxygen species (ROS) production and inhibits the activation of apoptotic pathways.
Pramipexole is a therapeutic agent for Parkinson′s disease and restless leg syndrome. It also exhibits antidepressant responses in patients suffering from MDD (major depressive disorder) and bipolar depression.
Features and Benefits
This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the Dopamine Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Boehringer Ingelheim. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - STOT SE 3
target_organs
Central nervous system
Classe di stoccaggio
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Scegli una delle versioni più recenti:
Possiedi già questo prodotto?
I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.
Natasa Kustrimovic et al.
Scientific reports, 6, 33738-33738 (2016-09-23)
Parkinson's disease (PD) is characterized by loss of dopaminergic neurons in substantia nigra pars compacta, α-synuclein (α-syn)-rich intraneuronal inclusions (Lewy bodies), and microglial activation. Emerging evidence suggests that CD4+ T lymphocytes contribute to neuroinflammation in PD. Since the mainstay of
Jose A Franco-Chaves et al.
Journal of affective disorders, 149(1-3), 319-325 (2013-03-23)
Antidepressants that act on two or more amine neurotransmitters may confer higher remission rates when first-line agents affecting a single neurotransmitter have failed. Pramipexole, a dopamine agonist, has antidepressant effects in patients with major depressive disorder (MDD). This pilot study
William Winlow
Core evidence, 1(1), 35-42 (2005-01-01)
Restless legs syndrome (RLS) affects 5-15% of adults, but is often unrecognized and consequently misdiagnosed. The International Restless Legs Scale (IRLS) has been developed and validated to assess the severity of RLS. Currently, the most common treatment for RLS is
Serdar Tort et al.
International journal of pharmaceutics, 579, 119164-119164 (2020-02-23)
Floating gastro-retentive delivery systems can prolong the gastric residence providing sustained drug release. In this study, we report on self-inflating effervescence-based electrospun nanofiber membranes embedding polyethylene oxide/sodium bicarbonate cast films. In this system, sodium bicarbonate results in an effervescence effect
Haritz Jiménez-Urbieta et al.
Neurobiology of aging, 75, 126-135 (2018-12-21)
Treatment with dopaminergic agonists such as pramipexole (PPX) contributes to the development of impulse control disorders (ICDs) in patients with Parkinson's disease (PD). As such, animal models of abnormal impulse control in PD are needed to better study the pathophysiology
Articoli
Discover Bioactive Small Molecules for ADME/Tox
We offer many products related to dopamine receptors for your research needs.
Numero articolo commerciale globale
| SKU | GTIN |
|---|---|
| A1237-10MG | 04061835257751 |
| A1237-50MG | 04061835257768 |
Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..
Contatta l'Assistenza Tecnica